ethyl 3-propylhexanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 3-propylhexanoate
• 英文别名: Ethyl 3-propylhexanoate
• 化学式: C₁₁H₂₂O₂
• 分子量: 186.294
• InChiKey: QVNVKXONAXUALG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 3-propylhexanoate 在 三溴化磷 作用下， 反应 1.5h， 生成 4-(2-bromoethyl)heptane
  参考文献：
  名称：

  Recherches sur les substances mesomorphes—IX

  摘要：

  DOI：

  10.1016/s0040-4020(01)92352-x
• 作为产物：
  描述：

  4-庚酮 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 mineral oil 为溶剂， 20.0 ℃ 、103.42 kPa 条件下， 反应 32.0h， 生成 ethyl 3-propylhexanoate
  参考文献：
  名称：

  [EN] LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS
  [FR] LIPIDES POUR L'ADMINISTRATION D'AGENTS THÉRAPEUTIQUES

  摘要：

  The current disclosure relates to lipid-based compositions and methods useful in administering therapeutic agents such as, for example, nucleic acids (e.g., siRNA, ASO, tRNA, miRNA, mRNA, DNA, and the like), proteins, peptides, and other macromolecules, which do not have the ability to easily cross a cell membrane. In particular, certain embodiments of the disclosure relate to reversible zwitterionic lipids having a tertiary amine with an increased pKa and extended linker domains (e.g., ≥C3), that may be incorporated into lipid-based compositions (e.g., lipid nanoparticles) to increase efficiency of delivery and release of a therapeutic agent(s) to a subject. The present disclosure provides compositions comprising such reversible zwitterionic lipids, optionally in association with a therapeutic agent (e.g., a therapeutic mRNA and/or nucleic acid controller system), as well as methods of synthesizing the ionizable lipid particle compositions provided herein.

  公开号：

  WO2023225621A2

文献信息

• Catalytic hydrogenation of α,β-unsaturated carboxylic acid derivatives using copper(<scp>i</scp>)/N-heterocyclic carbene complexes
  作者：Birte M. Zimmermann、Sarah C. K. Kobosil、Johannes F. Teichert

  DOI：10.1039/c8cc09853k

  日期：——

  air-stable copper(I)/N-heterocyclic carbene complex enables the catalytic hydrogenation of enoates and enamides, hitherto unreactive substrates employing homogeneous copper catalysis and H2 as a terminal reducing agent. This atom economic transformation replaces commonly employed hydrosilanes and can also be carried out in an asymmetric fashion.

  简单且空气稳定的铜（I）/ N-杂环卡宾络合物能够实现烯酸酯和烯酰胺的催化氢化，这是迄今为止使用均相铜催化和H 2作为末端还原剂的非反应性底物。这种原子经济的转变代替了常用的氢硅烷，并且也可以以不对称的方式进行。
• Iron‐Catalyzed Intermolecular Functionalization of Non‐Activated Aliphatic C−H Bonds <i>via</i> Carbene Transfer
  作者：Mònica Rodríguez、Gemma Font、Joel Nadal‐Moradell、Alberto Hernán‐Gómez、Miquel Costas

  DOI：10.1002/adsc.202000817

  日期：2020.11.18

  intermediates under mild reaction conditions has been an important challenge with attractive prospective in organic synthesis. In this work, we show the efficient combination of an electrophilic iron catalyst with a lithium Lewis acid for the functionalization of strong Csp3−H bonds of cyclic and linear alkanes by the activation of commercially available ethyl diazoacetate (EDA). The reaction proceeds with good

  在温和的反应条件下通过卡宾铁中间体对强C sp 3 -H键的修饰一直是重要的挑战，在有机合成中具有广阔的前景。在这项工作中，我们显示了亲电铁催化剂与路易斯酸锂的有效结合，用于通过活化市售重氮乙酸乙酯（EDA）活化环状和线性烷烃的强C sp 3 -H键。在温和的反应条件下（40°C），反应以良好的收率进行，不需要大量过量的底物。另外，在具有挑战性的脂族烯烃的环丙烷化中观察到优异的活性。
• Oxadiazolones, processes for their preparation and their use as pharmaceuticals
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP2083006A1

  公开（公告）日：2009-07-29

  The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinflammatory processes and/or other peripheral neuropathies.

  本发明涉及恶二唑酮及其生理上可接受的盐类和生理功能衍生物，它们具有 PPARdelta 激动剂活性。 所述的是式 I 的化合物、 的化合物、它们的生理学上可接受的盐及其制备工艺。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱、葡萄糖利用紊乱以及涉及胰岛素抵抗的紊乱；神经退行性疾病和/或中枢和周围神经系统的脱髓鞘疾病和/或涉及神经炎症过程和/或其他周围神经病的神经系统疾病。
• Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
  申请人：ModernaTX, Inc.

  公开号：US11066355B2

  公开（公告）日：2021-07-20

  The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

  本公开的特征是新型脂质和涉及新型脂质的组合物。脂质纳米颗粒（如空 LNPs 或负载 LNPs）包括新型脂质以及磷脂、结构脂质和 PEG 脂质等其他脂质。脂质纳米颗粒（如空LNPs或负载LNPs）进一步包括治疗和/或预防剂，如RNA，可用于向哺乳动物细胞或器官输送治疗和/或预防剂，以调节多肽、蛋白质或基因表达等。
• WO2021055833A5
  申请人：——

  公开号：WO2021055833A5

  公开（公告）日：2023-09-26